Результаты поиска

Ранняя интенсивная терапия в сравнении со стратегией эскалации во франко-карибской группе склероза.

ОКРУЖАЮЩАЯ СРЕДА: Данных о стратегии " Эскалация - терапия и ранняя интенсивная терапия " (ЭИТ) при множественном склерозе (МС) не имеется, особенно в афрокарибских случаях, известных своей строгостью. ЦЕЛИ: Оценка эффективности и безопасности этих стратегий применительно к преимущественно афрокарибскому населению, возвращающемуся в атмосферу. МЕТОДЫ: Многоцентральное ретроспективное исследование 195 пациентов с НР, в том числе 66 пациентов на СПЭ, с последующими исследованиями в течение ≥2 лет. ПРИМЕНИТЕЛЬНЫЕ РЕЗУЛЬТАТЫ: Кривые Каплан-Мейер и логарифмическая проверка использовались

Витамины D и нейродегенеративные заболевания, такие, как множественный склероз (MS), болезнь Паркинсона (PD), болезнь Альцгеймера (AD) и амиотропический боковой склероз (ALS): Обзор текущей литературы.

ЦЕЛЬ ОБЗОРА: В настоящем обзоре изучается роль витамина D3 и его производных в качестве ингибиторов патологических метаболических изменений в нейродегенеративных заболеваниях. В рукописи изучается, как витамин D3 влияет на регулирование нейронного кальция, антиоксидативные пути, иммуномодуляцию и нейрозащиту во время детоксификации, выходящие за пределы его известных функций кишечника, кости и почечной кальция и фосфора, а также минерализацию кости. Последние исследования показали синтез активного метаболита 1,25(OH)2D3 (витамин D) в глиальных клетках через процесс гидроксиляции CY-P24A1, ферм

Нарушения сна у пациентов с множественным склерозом.

Множественный склероз (МС), от которого в 2020 году во всем мире пострадало около 2,8 миллиона человек, часто связан с расстройствами сна. Эти нарушения могут быть вызваны самим заболеванием, таким, как боль или побочные эффекты симптоматического и иммунологического лечения. МЕТОДЫ: Настоящее исследование представляет собой межсекторальное аналитическое исследование. Обследованное население состоит из пациентов с НР, проживающих в городе Кашан. Расследуемый размер выборки состоит из 174 пациентов с диагнозом MS. Эта информация была собрана с помощью демографических информационных вопросников,

Case Report: AL Amyloidosis Severe Restrictive Cardiomyopathy Associated With Multiple Myeloma-Diagnostic Difficulties.

BackgroundCardiac AL amyloidosis as a complication of multiple myeloma (MM) is a formidable life-threatening condition. The first-line therapy for both MM and systemic AL amyloidosis is proteasome inhibitors (PIs). Unfortunately, the use of PIs may lead to cardiovascular toxicity development, which requires specific cardio-oncology supervision.Case reportA 57-year-old woman was admitted to a university hospital with clinical manifestation of progressive chronic heart failure. The patient had hypertension and no history of diabetes mellitus, myocardial infarction (MI), stroke, and arrhythmias.

Overcoming obstacles to repurposing for neurodegenerative disease.

Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer's Drug Discovery Foundation (ADDF) and the Michael J. Fox Foundation for Parkinson's Research (MJFF) convened an advisory panel in October 2013 to understand stakeholder perspectives related to repurposing FDA-approved drugs for neurodegenerative diseases. Here, we present opportunities on how philanthropy, industry, and government can begin to a

Advances in drug therapy for systemic lupus erythematosus.

Systemic lupus erythematosus (SLE) is an autoimmune disorder that afflicts 500,000 people in the United States. There has not been a new SLE drug approved in the United States since 1958. However, a guidance document issued by the Food and Drug Administration in 2005 provided a roadmap for investigators which spawned numerous ongoing clinical trials. Among these, Belimumab, a monoclonal antibody to soluble B lymphocyte stimulator, met its primary endpoints in two large trials and will probably obtain FDA approval soon. Other promising agents targeting a variety of mechanisms of action are curr

Treatment-free survival to bortezomib combined with dexamethasone in patients with refractory/relapsed pure red cell aplasia: a prospective clinical study.

BackgroundImmunosuppressive treatments induce and maintain remissions in a majority of patients with acquired pure red cell aplasia (aPRCA); however, salvage therapy for non-responders remains unsatisfactory.MethodsIn this prospective, open-label, clinical trial (NCT04423367), patients with refractory/relapsed aPRCA were recruited and received subcutaneous bortezomib at 1.3 mg/m2 in combination with dexamethasone 40 mg weekly(BD regimen) for 12 weeks. The primary endpoint was the overall response rate at 12 weeks.ResultsIn total, 18 patients were enrolled, including 10 (55.6%) with primary aPR

Time-dependent clearance can confound exposure-response analysis of therapeutic antibodies: A comprehensive review of the current literature.

Exposure-response (ER) analysis is used to optimize dose and dose regimens during clinical development. Characterization of relationships between drug exposure and efficacy or safety outcomes can be utilized to make dose adjustments that improve patient response. Therapeutic antibodies typically show predictable pharmacokinetics (PK) but can exhibit clearance that decreases over time due to treatment. Moreover, time-dependent changes in clearance are frequently associated with drug response, with larger decreases in clearance and increased exposure seen in patients who respond to treatment. Th

Emerging new therapeutic antibody derivatives for cancer treatment.

Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells. The successful application of IgG monoclonal antibodies has inspired the development of various types of therapeutic antibodies, such as antibody fragments, bispecific antibodies, and antibody derivatives (e.g., antibody-drug conjugates and immunocytokines). The miniaturization and multifunctionalization of antibodies are flexible and viable strategies for diagnosing or treating malignant tumors in a complex t

Adjuvant A-PRF Application in Patients with Various Stages of Medication-Related Osteonecrosis of the Jaw (MRONJ): Case Series.

Background and Clinical Significance: Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication of antiresorptive therapies such as Zolendronic acid, used for bone metastases. Its management remains challenging, with outcomes often unpredictable. Platelet-rich fibrin (PRF), rich in growth factors, has been proposed as a potential adjunct to surgical treatment, aiming to promote tissue regeneration and improve patient outcomes. Case Presentation: We reported three clinical cases of MRONJ in patients previously treated with Zolendronic acid. All patients underwent surgical seq

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.

AbstractMultiple myeloma (MM) survival rates have been substantially increased thanks to novel agents that have improved survival outcomes and shown better tolerability than treatments of earlier years. These new agents include immunomodulating imide drugs (IMiD) thalidomide and lenalidomide, the proteasome inhibitor bortezomib (PI), recently followed by new generation IMID pomalidomide, monoclonal antibodies daratumumab and elotuzumab, and next generation PI carfilzomib and ixazomib. However, even in this more promising scenario, febrile neutropenia remains a severe side effect of antineoplas

Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study.

We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22), autologous (18)) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylaxis. Patients received a once daily subcutaneous injection of dalteparin 2500 anti-Xa i.u. commencing the day prior to starting HDCT, and continuing until day +30 post HSCT or hospital discharge, whichever came first. Dosage adjustments were made for patients developing renal failure. All bleeding ep

Ранний паллиативный уход против обычного гематологического ухода в множестве миелом: ретроспективное когортное исследование.

ЦЕЛИ: Несмотря на то, что ранний паллиативный уход (ПКН) полезен для острой миэлоидной лейкемии, мало что известно о значении ЭПК для множественной миеломы (ММ). Мы сопоставили показатели качества паллиативного ухода и ухода за пациентами в конце их жизни, при этом ММ, получающими ПВХ, с показателями пациентов, получивших обычную гематологическую помощь. МЕТОДЫ: Это наблюдение, ретроспективное исследование основывалось на 290 Последовательные пациенты с MM. Были абстрагированы следующие показатели: оказание психологической поддержки, оценка/регулирование боли, обсуждение целей ухода, содействи

Воздействие йоги на психическое здоровье лиц с аутоиммунными расстройствами: обзор.

В качестве одного из способов поддержания психического и физического здоровья и дополнительной терапии для лечения различных заболеваний был изучен йога. Совсем недавно она была изучена на предмет ее способности уменьшать подстрекательские маркеры, вызывающие различные заболевания. Это открывает возможности для ее потенциальной роли в качестве адъюнкт-терапии в таких подстрекательских дисфункциях, как аутоиммунные расстройства. Хотя имеется значительный объем данных о йоге и аутоиммунных заболеваниях, предыдущие обзоры в основном ограничивались физическими улучшениями, с которыми сталкиваются

Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

There is increasing emphasis on patient-centred research to support the development, approval and reimbursement of health interventions that best meet patients' needs. However, there is currently little guidance on how meaningful patient engagement may be achieved. An expert working group, representing a wide range of stakeholders and disciplines, was convened by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the World Health Organization (WHO). Through a structured, collaborative process the group generated pract

Investigating the therapeutic efficacy of psilocybin in advanced cancer patients: A comprehensive review and meta-analysis.

BackgroundPsilocybin, a naturally occurring psychedelic compound found in certain species of mushrooms, is known for its effects on anxiety and depression. It has recently gained increasing interest for its potential therapeutic effects, particularly in patients with advanced cancer. This systematic review and meta-analysis aim to evaluate the effects of psilocybin on adult patients with advanced cancer.AimTo investigate the therapeutic effect of psilocybin in patients with advanced cancer.MethodsA comprehensive search of electronic databases was conducted in PubMed, Cochrane Central Register

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.

Low plasma CsA concentrations (<300-350 ng/mL) early following allogeneic hematopoietic stem cell transplantation (HSCT) is associated with an increased risk of developing acute graft-versus-host disease (aGvHD). Nevertheless, the current optimal target trough concentration for CsA following HSCT is considered to be 200-400 ng/mL. Here, we performed a retrospective analysis of a homogeneous group of 129 patients who received HSCT after non-myeloablative conditioning, and we analyzed the impact of CsA trough concentration measured during the first four weeks (CsA W1-4) on the incidence aGvHD, r

Early detection of acute cisplatin nephrotoxicity: interest of urinary monitoring of proximal tubular biomarkers.

BackgroundRenal toxicity induced by cisplatin (CisPt) is a clinical issue in patients with or without chronic kidney disease (CKD). Proximal tubular injury can result in acute kidney injury (AKI), which may compromise the course of chemotherapy and the prognosis. The purpose of this study was to investigate the time course of urinary markers of acute tubulotoxicity and to assess the usefulness of such monitoring in a routine clinical setting.MethodsThis work is an open prospective pilot study carried out among 23 patients receiving a platinum-based chemotherapy. Individual comorbidities, plasm

Organic Nanoparticles in Progressing Cardiovascular Disease Treatment and Diagnosis.

Cardiovascular diseases (CVDs), the world's most prominent cause of mortality, continue to be challenging conditions for patients, physicians, and researchers alike. CVDs comprise a wide range of illnesses affecting the heart, blood vessels, and the blood that flows through and between them. Advances in nanomedicine, a discipline focused on improving patient outcomes through revolutionary treatments, imaging agents, and ex vivo diagnostics, have created enthusiasm for overcoming limitations in CVDs' therapeutic and diagnostic landscapes. Nanomedicine can be involved in clinical purposes for CV

Совпадение в полном тексте источника
… In Vitro Drug Release Testing of Special Dosage Forms. John Wiley & Sons Ltd.; Hoboken, NJ, USA: 2019. Drug-Eluting Stents; pp. 87–117. 61. Chen J., Song Y., Wang Q., Li Q., Tan H., Gao J., Zhang N., Weng X., Sun D., Yakufu W., et al. …

PROCEEDINGS 32nd Symposium ESVN-ECVN WROCLAW, POLAND 12th-14th September 2019. Selected research communications of the 32nd Symposium of the ESVN-ECVN Wroclaw, Poland 12th to 14th September 2019.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.